iBio, Inc.

Healthcare · Biotechnology · United States

Last price 0.8136 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 52.32M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company’s technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area...